|
|||||||||||||||||||||||||||||||||
| DATASHEET Historically, TRAIL-R3 has been referred to as tumor necrosis factor receptor superfamily member 10C precursor, Decoy receptor (DcR1), Decoy TRAIL receptor without death domain, TNF-related apoptosis-inducing ligand receptor 3, TRAIL receptor 3, Trail receptor without an intracellular domain, Lymphocyte inhibitor of TRAIL, Antagonist decoy receptor for TRAIL/Apo-2L, and CD263 antigen. TRAIL induces apoptosis in various types of malignant cells without affecting normal cells. TRAIL binds to receptors TRAIL-R1, TRAIL-R2, TRAIL-R3, and TRAIL-R4. Unlike the death receptors, TRAIL-R1 and TRAIL-R2, TRAIL-R3 and TRAIL-R4 bind TRAIL without apoptotic signaling. Specificity: This antibody recognizes human TRAIL-3 receptor and may cross-react with mouse TRAIL-R3 as Western blotting shows a similar size protein of ~33 kD from mouse spleen. TRAIL-R2 peptide from the same region does not bind to this antibody. For TRAIL-R1 there is low sequence homology in this region. This antibody may bind to TRAIL-R4. Formulation: Liquid 200 µg of affinity purified antibody in 10 mM KHPO4, 140 mM NaCl with 0.1 % sodium azide Quality Control: Western blot or Immunocytochemistry on cell lines HEK 293 or Jurkat. Storage: Freeze at -20 °C or colder. Stable for at least 3 years when stored at -80°C. Avoid freeze/thaw cycles. CIO112P - Blocking Peptide to Antibody $95 USD per 100 µg
|
For Research Purposes Only |
||||||||||||||||||||||||||||||||
Citations and Applications |
| Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B, Griffith TS, Sanlioglu S. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):716-23. Abstract IH |
| Aydin C, Sanlioglu AD, Karacay B, Ozbilim G, Dertsiz L, Ozbudak O, Akdis CA, Sanlioglu S. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells. Hum Gene Ther. 2007 Jan;18(1):39-50 Abstract IH |
| Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood. 2005 May 1;105(9):3413-9. Full Text FC |
| Spierings DC, de Vries EG, Vellenga E, van den Heuvel FA, Koornstra JJ, Wesseling J, Hollema H, de Jong S. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem. 2004 Jun;52(6):821-31. Full Text WB, IH |
Basile JR, Zacny V, Munger K. The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J Biol Chem. 2001 Jun 22;276(25):22522-8. Full Text WB |
Anti-actin, Capralogics Home, Chemokine Receptors,,Citations, Contact Us, Custom Polyclonal Antibody Services, FAQ, GLP Compliance, Diagnostic Antibody Production, Interleukins, IVD Antibodies, Licenses and Assurances, Polyclonal Antibody Production Services, "Scrapie Free" Goats, Toll-Like Receptors, TRAIL, Welcome to Capralogics
